首页|氟哌噻吨美利曲辛联合倍他司汀治疗对良性阵发性位置性眩晕复位后残余头晕患者眩晕程度及前庭功能的影响

氟哌噻吨美利曲辛联合倍他司汀治疗对良性阵发性位置性眩晕复位后残余头晕患者眩晕程度及前庭功能的影响

扫码查看
目的 探讨在良性阵发性位置性眩晕(BPPV)复位后残余头晕患者中使用氟哌噻吨美利曲辛联合倍他司汀治疗的影响.方法 选择 2020 年 10 月—2023 年 10 月金乡县人民医院收治的 84 例BPPV复位后残余头晕患者为研究对象,按随机数字表法将其分为对照组和观察组,各 42 例.对照组采用甲磺酸倍他司汀治疗,观察组在对照组基础上联合氟哌噻吨美利曲辛片治疗,两组均持续治疗 2 个月.对比两组的临床疗效、眩晕程度、前庭功能及不良反应发生情况.结果 观察组的治疗总有效率为 95.24%,高于对照组的 80.95%,差异有统计学意义(P﹤0.05).治疗前,两组眩晕障碍量表(DHI)、前庭症状指数(VSI)评分对比,组间差异无统计学意义(P﹥0.05);治疗后,观察组DHI、VSI评分均较对照组低,组间差异有统计学意义(P﹤0.05).两组不良反应发生率对比,差异无统计学意义(P﹥0.05).结论 氟哌噻吨美利曲辛联合倍他司汀治疗BPPV复位后残余头晕患者的效果显著,有利于减轻患者的眩晕程度,可改善其前庭功能,且安全性良好.
Effects of Flupentixol and Melitracen Combined with Betahistine on the Degree of Dizziness and Vestibular Function in Patients with Residual Dizziness after Reduction of Benign Paroxysmal Positional Vertigo
Objective To investigate the effect of flupentixol combined with melitracen and betahistine in patients with residual dizziness after reduction of benign paroxysmal positional vertigo(BPPV).Methods A total of 84 patients with residual dizziness after reduction of BPPV in Jinxiang County People's Hospital from October 2020 to October 2023 were selected as the research objects,and were divided into a control group and an observation group according to random number table method,with 42 cases in each group.The control group was treated with betahistine mesylate and the observation group was treated with flupentixol melitracen tablets on the basis of the control group,both groups were treated for 2 months.The clinical efficacy,dizziness degree,vestibular function and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 95.24%,which was higher than 80.95%of the control group,and the difference was statistically significant(P﹤0.05).Before treatment,there was no significant difference in Dizziness Handicap Inventory(DHI)and Vestibular Symptom Index(VSI)scores between the two groups(P﹥0.05);after treatment,DHI and VSI scores in the observation group were lower than those in the control group,and the differences between the groups were statistically significant(P﹤0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P﹥0.05).Conclusion The flupentixol and melitracen combined with betahistine in the treatment of residual dizziness after reduction of BPPV has a significant effect,which is conducive to reducing the degree of dizziness and improving the vestibular function of patients,and has good safety.

Residual dizziness after reduction of benign paroxysmal positional vertigoFlupentixol and melitracenBetahistineDegree of dizzinessVestibular function

杨丹

展开 >

金乡县人民医院神经内科,山东 济宁 272000

良性阵发性位置性眩晕复位后残余头晕 氟哌噻吨美利曲辛 倍他司汀 眩晕程度 前庭症状指数

2024

反射疗法与康复医学

反射疗法与康复医学

ISSN:
年,卷(期):2024.5(19)